Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo: Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
IPO
Business /  Companies

Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China’s domestic market

  • CanSino Biologics jumped 59 per cent in debut trading in Hong Kong on Thursday, reflecting the best first day trading gain in the city since 2017
  • Steve Chao, chief operating officer, says the company has 15 vaccines under development

Topic |   IPO
Zoe Low
Zoe Low

Updated: 10:13pm, 29 Mar, 2019

Why you can trust SCMP
Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo: Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
Cansino Biologics became the first vaccine maker to list on the Hong Kong Stock Exchange this week, thanks to listing reforms which permit pre-revenue biotech companies and tech companies to raise capital in the city. Photo:
READ FULL ARTICLE